Researchers were able to molecularly classify endometrial cancers with distinct survival differences using a new classification tool called ProMisE that uses clinically applicable methods.
ASCO 2016 Gynecologic Cancers
A concurrent chemotherapy and radiotherapy regimen with cisplatin and paclitaxel yielded a good response rate and strong long-term survival outcomes in patients with locally advanced or recurrent cervical cancer.
In this video Dr. Odunsi discusses a new study that found that higher T-cell diversity in ovarian cancer is associated with poor overall survival.
A live attenuated bioengineered bacteria-vectored vaccine immunotherapy is well tolerated and appears to be associated with promising overall survival among women with persistent/recurrent metastatic cervical cancer.
Baseline quality of life measures predict early cessation of chemotherapy and overall survival in women with platinum-resistant/refractory, recurrent ovarian cancer.
Despite hematologic toxicities and port-related adverse events, IP carboplatin plus IV dose-dense paclitaxel appears to be effective in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.
Extending platinum-free interval with pegylated liposomal doxorubicin, topotecan, or gemcitabine does not improve overall survival among patients with recurrent ovarian cancer.
Pembrolizumab is well-tolerated and shows promising antitumor activity and early survival rates among patients with PD-L1–positive cervical squamous cell cancer, according to preliminary results of the KEYNOTE-028 trial.
Adding metformin to a combination of everolimus plus letrozole for women with advanced or recurrent endometrioid endometrial cancer might offer clinical benefits.
Hormone maintenance therapy is associated with better survival than post-treatment surveillance for women with low-grade serous carcinoma of the ovary or peritoneum.